Heparin-coated circuits (Duraflo II) with reduced versus full anticoagulation during coronary artery bypass surgery

Journal of Cardiac Surgery

Volumn 18, Issue 2, 2003, Pages 140-146

  Øvrum, Eivind ^a   Tangen, Geir ^a   Øystese, Rolf ^a   Ringdal, Mari Anne L ^a   Istad, Reidar ^a  

^a Oslo Heart Center   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; PROTAMINE;

ADULT; AGED; ANTICOAGULANT THERAPY; ASSISTED VENTILATION; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CONFERENCE PAPER; CORONARY ARTERY BYPASS SURGERY; DRUG EFFECT; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART REHABILITATION; HEMOGLOBIN DETERMINATION; HEPARINIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MATERIAL COATING; NEUROLOGICAL COMPLICATION; POSTOPERATIVE HEMORRHAGE; STROKE; SURGICAL MORTALITY;

AGED; ANTICOAGULANTS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERY BYPASS; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SAMPLING STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037365287     PISSN: 08860440     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8191.2003.02007.x     Document Type: Conference Paper

References (22)

1. Videm V, Svennevig JL, Fosse E, et al: Reduced complement activation with heparin-coated oxygenator, and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 1992;103:806-813.
2. Gu YJ, van Oeveren W, Akkerman C, et al: Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55:917-922.
3. Fosse E, Moen O, Johnson E, et al: Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1994;58:472-477.
4. Weerwind PW, Maessen JG, van Tits LJH, et al: Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass. J Thorac Cardiovasc Surg 1995;110:1633-1641.
5. Von Segesser LK, Weiss BM, Pasic M, et al: Risk and benefit of low systemic heparinization during open heart operations. Ann Thorac Surg 1994;58:391-398.
6. Øvrum E, Åm Holen E, Tangen G, et al: Completely heparinized cardiopulmonary bypass and reduced systemic heparin: Clinical and hemostatic effects. Ann Thorac Surg 1995;60:365-371.
7. Aldea GS, Doursounian BA, O'Gara P, et al: Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: A prospective, randomized study. Ann Thorac Surg 1996;62:410-418.
8. Svenmarker S, Sandstrom E, Karlsson T, et al: Clinical effects of the heparin-coated surface in cardiopulmonary bypass. Eur J Cardio-thorac Surg 1997;11:957-964.
9. Øvrum E, Tangen G, Øystese R, et al: Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass surgery. J Thorac Cardiovasc Surg 2001;121:324-330.
10. Øvrum E, Åm Holen E, Tangen G: Consistent non-pharmacologic blood conservation in primary and reoperative coronary artery bypass grafting. Eur J Cardio-thorac Surg 1995;9:30-35.
11. Aldea G, O'Gara P, Shapira OM, et al: Effect of anti-coagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits. Ann Thorac Surg 1998;65:425-433.
12. Øvrum E, Åm Holen E, Tangen G, et al: Heparinized cardiopulmonary bypass and full heparin dose marginally improve clinical performance. Ann Thorac Surg 1996;62:1128-1133.
13. Wildevuur CRH, JansenPGM, Bezemer PD, et al: Clinical evaluation of Duraflo II heparin-treated extracorporeal circulation circuits (2d version): The European working group on heparin-coated extracorporeal circulation circuits. Eur J Cardio-thorac Surg 1997;11:616-623.
14. Ranucci M, Mazzucco A, Pessotto R, et al: Heparin-coated circuits for high-risk patients: A multicenter, prospective, randomized trial. Ann Thorac Surg 1999;67:944-1000.
15. Flom-Halvorsen HI, Øvrum E, Tangen G, et al: Autotransfusion in coronary artery bypass grafting: Disparity in laboratory tests and clinical performance. J Thorac Cardiovasc Surg 1999;118:610-617.
16. Khuri SF, Valeri CR, Loscalzo J, et al: Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995;60:1008-1014.
17. Øvrum E, Brosstad F, Åm Holen E, et al: Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. Circulation 1995;92:2579-2584.
18. Shapira N, Schaff HV, Piehler JM, et al: Cardiovascular effects of protamine sulfate in man. J Thorac Cardiovasc Surg 1982;84:505-514.
19. Svenmarker S, Sandström E, Karlsson T, et al: Neurological and general outcome in low-risk coronary artery bypass patients using heparin-coated circuits. Eur J Cardio-thorac Surg 2001;19:47-53.
20. Øvrum E, Mollnes TE, Fosse E, et al: High and low heparin dose with heparin-coated cardiopulmonary bypass: Activation of complement and granulocytes. Ann Thorac Surg 1995;60:1755-1761.
21. Øvrum E. Eosinophil granulocyte activation and heparin-coated cardiopulmonary bypass (letter). Ann Thorac Surg 1996;61:1038-1039.
22. Creswell LL, Schuessler RB, Rosenbloom M, et al: Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 1993;56:539-549.